Vaccine therapy using rgp 160 in early HIV infection.
R
R
Redfield
D
D
Birx
N
N
Ketter
V
V
Polonis
S
S
Johnson
C
C
Davis
G
G
Smith
C
C
Oster
D
D
Burke
D015496:CD4-Positive T-Lymphocytes; D015686:Gene Products, env / Q000276:immunology / Q000627:therapeutic use*; D015483:HIV Antibodies / Q000096:biosynthesis; D019302:HIV Envelope Protein gp160; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D016233:Immunotherapy, Active; D007958:Leukocyte Count; D011498:Protein Precursors / Q000276:immunology / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use*
D015686:Gene Products, env; D015483:HIV Antibodies; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic